Semaglutide Dosage Chart and Schedule
FDA-approved
Weekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).
Also called: Ozempic, Wegovy, Rybelsus, Wegovy HD
Regulatory status (US)
FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy injection (weight, 2021), Wegovy tablets (25 mg, December 2025), Wegovy HD (7.2 mg weekly, March 2026) and Rybelsus tablets. The semaglutide shortage was declared over in February 2025.
What it is
A GLP-1 receptor agonist peptide with a half-life of about one week, given as a weekly injection or a daily tablet.
Wegovy injection label escalation
| Weeks | Weekly dose | Note |
|---|---|---|
| 1-4 | 0.25 mg | Starting dose |
| 5-8 | 0.5 mg | |
| 9-12 | 1 mg | |
| 13-16 | 1.7 mg | |
| 17+ | 2.4 mg | Maintenance (or 1.7 mg) |
| After 4+ weeks on 2.4 mg | up to 7.2 mg | Adults, weight reduction (Wegovy HD) |
From the Wegovy prescribing information. Ozempic (diabetes) uses 0.25 mg for 4 weeks, then 0.5 mg, then 1 mg and a maximum of 2 mg, each step after at least 4 weeks.
Semaglutide reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe. A units chart for every dose step is on the Semaglutide reconstitution calculator page.
What human studies show
- Approved on the basis of the SUSTAIN, STEP and SELECT programs; dosing below is from the current labels.
Storage
- Ozempic pen: refrigerate before first use; after first use it keeps 56 days at 15-30 °C or in the fridge.
- Never share pens, even with a new needle.
Safety
- Boxed warning: risk of thyroid C-cell tumors (medullary thyroid carcinoma, MEN 2).
- Warnings include pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury, severe GI reactions, diabetic retinopathy and aspiration under anesthesia.
- The FDA has reports of people taking 5 to 20 times the intended dose of compounded semaglutide by confusing units and mL, some needing hospital care.
Compare
Questions
- Is Semaglutide FDA-approved?
- FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy injection (weight, 2021), Wegovy tablets (25 mg, December 2025), Wegovy HD (7.2 mg weekly, March 2026) and Rybelsus tablets. The semaglutide shortage was declared over in February 2025.
- What dose of Semaglutide has been studied?
- 1-4: 0.25 mg: Starting dose; 5-8: 0.5 mg; 9-12: 1 mg; 13-16: 1.7 mg; 17+: 2.4 mg: Maintenance (or 1.7 mg); After 4+ weeks on 2.4 mg: up to 7.2 mg: Adults, weight reduction (Wegovy HD). From the Wegovy prescribing information. Ozempic (diabetes) uses 0.25 mg for 4 weeks, then 0.5 mg, then 1 mg and a maximum of 2 mg, each step after at least 4 weeks.
- How many units is my Semaglutide dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.
Orforglipron (Foundayo)Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.
TesamorelinGHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.
Elamipretide (SS-31)Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.
Sources
- Wegovy (semaglutide) US prescribing information, Novo Nordisk
- Ozempic (semaglutide) US prescribing information, Novo Nordisk
- Rybelsus (semaglutide tablets) US prescribing information
- FDA approves higher-dose semaglutide under the national priority voucher program (Mar 2026)
- FDA: Dosing errors associated with compounded semaglutide
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.